Patient Assistance Programs for Minivelle Patient assistance programs (PAPs) are usually sponsored by pharmaceutical companies and provide free or discounted medicines to low income or uninsured and under-insured people who meet specific guidelines. Eligibility requirements vary for each program.
Full Answer
What is in minivelle used to treat?
MINIVELLE is used to reduce moderate to severe hot flashes due to menopause and to help prevent postmenopausal osteoporosis (thin weak bones). The 0.025 mg/day dose is only approved for the prevention of postmenopausal osteoporosis.
Where can I buy minivelle?
Noven markets and sells MINIVELLE through the women’s health unit of its specialty pharmaceuticals subsidiary, Noven Therapeutics, LLC. MINIVELLE is also available as an authorized generic.
Can minivelle be used to prevent osteoporosis from menopause?
The 0.025 mg/day dose is only approved for the prevention of postmenopausal osteoporosis. If you use MINIVELLE only to prevent osteoporosis from menopause, talk with your healthcare provider about whether a different treatment or medicine without estrogens might be better for you.
What is the goal of the Patient Assistance Program?
Our goal is to invest our resources to help the most patients with the greatest need, including senior citizens and families with limited incomes.
How much does a free drug card save?
The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.
Is Minivelle a generic?
Prices are for cash paying customers only and are not valid with insurance plans. A generic version of Minivelle has been approved by the FDA. However we either do not have pricing information for it, or it is not commercially available. More info: generic Minivelle availability.
What is BI Cares?
The BI Cares Patient Assistance Program is a charitable program provided by the Boehringer Ingelheim Cares Foundation (BI Cares), an independent nonprofit organization, to improve patients’ health and lives.
Is Boehringer Ingelheim Cares affiliated with any third party?
The Boehringer Ingelheim Cares Foundation is not affiliated with any third party individual or organization that may charge patients a fee (s) to assist them in applying to our program or ordering refills through our program. These individuals or organizations are acting independently of the Boehringer Ingelheim Cares Foundation and do not have the Foundation’s consent.
What is Noven patient support?from noven.com
Noven’s newly created patient support program connects patients to product information resources, helps them understand product-related coverage, and also helps them find out if they’re eligible for co-pay assistance.
What is Noven's mission?from noven.com
Noven’s Mission: To develop and offer pharmaceutical products that meaningfully benefit patients around the world, with a commitment to advancing patient care through transdermal drug delivery.
What is a Noven patch?from company-histories.com
Noven Pharmaceuticals, Inc. is a Miami-based company devoted to the development of transdermal drug delivery products. The company uses a small adhesive patch worn on a patient's skin to provide controlled delivery of a drug for a defined period of time, thereby improving patient compliance. Concentrating on the delivery of existing drugs, Noven has been able to focus its research and development efforts on improving transdermal technology, making Noven an industry leader and resulting in the development of much smaller patches that in addition to improving patient comfort allow for patch versions of drugs that would have previously been too large to wear. Noven's advanced technology also allows two drugs to be delivered on one small patch, such as its CombiPatch product that offers both estrogen and progestin to menopausal and post-menopausal women in the United States. Other Noven products, sold through its licensees, include Estalis, the European version of CombiPatch; Vivelle, an estrogen patch for the U.S. market; Menorest, an estrogen patch for the European market; Vivelle-Dot, the U.S. version of a later generation estrogen patch, the world's smallest; and Estradot, the European version of Vivelle-Dot. In addition, Noven directly markets DentiPatch, a product used by dentists as a preliminary anesthetic.
How did Noven get its money?from company-histories.com
In the months after the failed merger with Ivax, Noven was able to secure much needed cash by signing licensing deals for its estrogen patch with two giant pharmaceuticals while retaining its freedom. Obtaining rights to the United States and Canada was Ciba-Geigy, which had been selling its own patch before concluding that Noven's product, named Vivelle for the North American market, was superior. Ciba decided to market Noven's patch as its own, acquiring warrants that would allow it to purchase a 7.6 percent stake in Noven. The French firm of Rhone-Poulenc Rorer (RPR) obtained rights to the rest of the world for the 10-day estrogen patch. To raise further cash, Noven held a secondary stock offering that netted $17.7 million. Because its licensees would require an overabundance of available product before marketing the estrogen patch, Noven had to expand its production capacity. Management considered moving the company to Pennsylvania, close to RPR's U.S. headquarters in Philadelphia, but officials in Dade County, Florida, were eager to keep Noven and offered a number of incentives to stay. Not only did Noven receive economic aid in labor recruitment and training, the county smoothed the way on zoning waivers and provided quick approval on water and sewage permits. As a consequence, Noven was able to purchase and lease a total of 100,000 square feet in three buildings located on 15 acres of land in South Dade County.
What is Noven Pharmaceuticals?from noven.com
is a dynamic specialty pharmaceutical company engaged in the research, development, manufacture, marketing, and sale of prescription pharmaceutical products. We are committed to developing and offering pharmaceutical products that meaningfully benefit patients, with a commitment to advancing patient care through transdermal drug delivery.
How long has Noven been in business?from noven.com
With over 130 years of combined experience, the Noven Executive Team is comprised of a diverse group of leaders working towards a common goal of benefiting patients around the world through innovative transdermal drug technologies.
When did Noven start selling vivelle?from company-histories.com
Although Noven's new manufacturing plant had still not received FDA approval, Ciba (soon to become part of Novartis AG) decided in the spring of 1996 to finally start marketing Vivelle, after experiencing a 7 percent drop-off in sales of its older patch. This turn of events resulted in an surge of investor confidence, which would more than double the price of Noven stock. Such volatility in the price of the company's stock would be commonplace over the next few years. By the spring of 1997 the stock was again trading at the $8 level, due to lower levels of reorders as the company worked through its stockpile of estrogen patches. Noven hoped to improve its fortunes, and move closer to its elusive goal of profitability, when it introduced its second product, DentiPatch, in 1997. The adhesive strip filled with lidocain was designed to numb the mouth within two minutes and remain effective for 45 minutes, allowing a dentist to painlessly introduce a needle to the area. Although a positive step, Noven lost close to $9.6 million in 1997.
Is Novartis responsible for third party websites?
Novartis is not responsible for the content of third-party websites.
Does Novartis have a copay card?
At Novartis Pharmaceuticals Corporation, we know that access to your medication is important. That's why we created a prescription co-pay savings program that's simple to use and can help eligible patients with out-of-pocket costs. It's easy to find out if you're eligible and to activate your co-pay card. Select your medication below to get started.
